Financial reports
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2022 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
2 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
3 Mar 22
Current reports
8-K
Other Events
19 Mar 24
8-K
Puma Biotechnology Reports Fourth Quarter and Full Year
29 Feb 24
8-K
Regulation FD Disclosure
18 Jan 24
8-K
Puma Biotechnology Reports Third Quarter 2023 Financial Results
2 Nov 23
8-K
Regulation FD Disclosure
26 Sep 23
8-K
Amendments to Articles of Incorporation or Bylaws
18 Aug 23
8-K
Puma Biotechnology Reports Second Quarter Financial Results
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
Puma Biotechnology Reports First Quarter Financial Results
4 May 23
8-K
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
2 Mar 23
Registration and prospectus
424B3
Prospectus supplement
2 Aug 22
S-3
Shelf registration
22 Jul 22
424B5
Prospectus supplement for primary offering
4 Nov 21
S-8
Registration of securities for employees
16 Sep 21
S-3
Shelf registration
2 Jul 21
S-8
Registration of securities for employees
27 Feb 20
S-8
Registration of securities for employees
19 Jul 17
S-8
Registration of securities for employees
31 May 17
25
Voluntary exchange delisting
30 Dec 16
8-A12B
Registration of securities on exchange
30 Dec 16
Proxies
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
26 Apr 21
DEF 14A
Definitive proxy
26 Apr 21
PRE 14A
Preliminary proxy
2 Apr 21
DEFA14A
Additional proxy soliciting materials
27 Apr 20
DEF 14A
Definitive proxy
27 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 19
Other
EFFECT
Notice of effectiveness
2 Aug 22
CORRESP
Correspondence with SEC
28 Jul 22
UPLOAD
Letter from SEC
27 Jul 22
EFFECT
Notice of effectiveness
14 Jul 21
CORRESP
Correspondence with SEC
8 Jul 21
UPLOAD
Letter from SEC
8 Jul 21
CT ORDER
Confidential treatment order
19 Mar 19
UPLOAD
Letter from SEC
8 Feb 19
CORRESP
Correspondence with SEC
21 Dec 18
UPLOAD
Letter from SEC
10 Dec 18
Ownership
SC 13G
Frazier Life Sciences Public Fund, L.P.
29 Mar 24
4
ALAN H AUERBACH
19 Mar 24
4
Alvin F Wong
14 Feb 24
4
MAXIMO F NOUGUES
14 Feb 24
4
Jeffrey Jerome Ludwig
14 Feb 24
4
ALAN H AUERBACH
14 Feb 24
4
DOUGLAS M HUNT
14 Feb 24
SC 13G/A
Camber Capital Management LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
ACORN BIOVENTURES, L.P.
6 Feb 24